Services

Market Access and Commercialization

We help life sciences companies successfully initiate and sustain product commercialization.

Overview

Increasingly Complex Launch Environment

The journey from research and development through product launch is seldom straightforward and never guaranteed. Now the inherent complexities of market entry are being compounded by new variables, including coverage-with-evidence requirements, shifting sales models, and ongoing supply chain disruptions.

Reducing go-to-market risk in the endemic era requires heightened coordination across the organization and significant business model adjustments. Proof points of safety and efficacy must be augmented by evidence of value. With in-person sales calls reduced, organizations need to embrace digital sales strategies to build clinician engagement.

Defining Market Access and Commercialization

Market access and commercialization encompasses the successive steps required to develop and support a life sciences product launch. During the R&D phase, treatment gap identification and the competitive environment must be properly assessed; in pre-launch, channel strategies and pricing defined. Finally, ongoing stakeholder engagement and evidence generation to support global product expansion are critical in the post-launch phase.

Our Approach

Avalere’s One-Stop Approach

Avalere’s cross-functional team partners with life sciences companies to deliver expert guidance at each point along the access-and-commercialization continuum. With a deep understanding of the current market landscape, we will support you in developing solutions to reduce the impact of out-of-pocket expenses of Part D, support strategic pricing and contracting for novel product market entry and provide innovative distribution, and supply chain strategies.

At the outset, we’ll help assess the burden of illness, identify treatment gaps, and conduct market sizing. We can then design clinical studies and calculate value and cost-avoidance projections. Pre-launch, we will work with you to develop appropriate pricing, assist with payer and provider segmentation, gauge the regulatory and policy landscape, and implement the optimal distribution approach. The latter step can include navigating logistical challenges associated with direct-to-patient distribution for novel therapeutics.

Our post-launch support includes optimizing patient identification and the patient journey, real-world evidence generation and dissemination, registry development, price modeling, value-messaging, and customer communication.

Additionally, we support clients with ongoing insights and market access and commercial strategy refinement as the market evolves, and as products age through their lifecycle.

Underlying Avalere’s portfolio of market access and commercialization services is empirical knowledge developed through our industry-leading data and analytics capabilities. By matching our vast pool of available data with advanced analytics, we’re able to develop the insights and intelligence required to drive informed, pro-active decisions at every step.

Our experts are particularly focused on the following therapeutic areas:

Oncology
Autoimmune
Vaccines
Rare disease
Cell and gene therapy
Kidney care
HIV

Market Access Strategic Plan
Market Assessment	Pre-Launch Planning	Commercialization Readiness	Market Strategy


Pipeline strategy and asset prioritization Total addressable market identification Treatment gaps and patient journey analysis Clinical trial endpoint and site identification	Provider and payer insights, payer mix, and standard of care mix identification Target product profile development and payer willingness-to-pay assessment Product-to-patient strategy Regulatory engagement strategy	Value proposition development Pricing and net pricing strategy Launch planning and readiness support Coding and reimbursement strategy and execution Coverage strategy development Customer-facing launch model build-out Contracting strategy creation	Post-launch insights leading to access strategy refinement Drug pricing and payment reform analysis, gross-to-net impact assessment Value framework impact analysis Payer, access, bid, and formulary negotiations support Life cycle management

Market Access Strategic Plan


Market Assessment
Pipeline strategy and asset prioritization Total addressable market identification Treatment gaps and patient journey analysis Clinical trial endpoint and site identification

Pre-Launch Planning
Provider and payer insights, payer mix, and standard of care mix identificationTarget product profile development and payer willingness-to-pay assessmentProduct-to-patient strategyRegulatory engagement strategy

Commericalization Readiness
Value proposition development Pricing and net pricing strategy Launch planning and readiness support Coding and reimbursement strategy and execution Coverage strategy development Customer-facing launch model build-out Contracting strategy creation

Market Strategy
Post-launch insights leading to access strategy refinement Drug pricing and payment reform analysis, gross-to-net impact assessment Value framework impact analysis Payer, access, bid, and formulary negotiations support Loss of exclusivity strategic planning